An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Lenvatinib (Primary) ; Midazolam
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 24 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2018.
- 13 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2016.
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.